Lineage Logistics Strengthens European Transport Capability and Expands Benelux Footprint
Lineage Logistics, LLC (“Lineage” or the “Company”), one of the world’s leading temperature-controlled industrial REIT and logistics solutions providers, today announced the acquisitions of Van Tuyl Logistics, H&S Coldstores and Frigocare Rotterdam BV. These strategic transactions will strengthen Lineage’s portfolio of end-to-end logistics solutions in the region and grow Lineage’s presence in the Netherlands by more than 250,000 cubic metres of capacity.
Based in Gameren, Van Tuyl Logistics is a Dutch provider of temperature-controlled logistics that specialises in refrigerated and frozen transport. Van Tuyl employs a modern fleet of 60 trucks and 90 trailers with a self-owned repair station, in addition to warehousing services for 30,000 pallet spaces at different temperatures and a real estate holding division.
“We are pleased to welcome Van Tuyl Logistics into the One Lineage Family as we continue to build momentum and further expand our European operations,” said Harld Peters, Senior Vice President, Europe at Lineage. “The Netherlands remains a critical hub for the food cold chain within the European market, given its central location and accessibility to key seaports and inland terminals. Accordingly, the addition of Van Tuyl will help Lineage to connect more points across our customers’ extended supply chains.”
“We know that Lineage is the right partner for the next stage in our company’s history and in our ambition to reimagine the journey of food,” said Richard van Tuijl, General Director of Van Tuyl Logistics. “Our end-to-end solutions complement Lineage’s strong and growing presence in Europe, and we are confident that our customers will continue to be well-served as we combine our logistics and cold storage operations.”
Lineage also acquired Dutch provider H&S Coldstores and its logistics forwarding business from the H&S Group, Europe’s largest intermodal Liquid Food operator.
Headquartered in Beneden-Leeuwen, H&S Coldstores provides end-to-end juice supply chain services, including transport, warehousing, customs, production, processing, laboratory testing, and packaging solutions. The logistics forwarding business from H&S Group also offers a pan-European network of more than 250 privately owned and subcontracted vehicles as well as more than 1,500 tank units for the liquid foodstuff industry.
In total, this acquisition will add a capacity of 48,000 tonnes to Lineage’s footprint in Europe. The H&S Coldstores facilities in Elst and Tiel will be moved to a new location in a newly built facility, closer to other existing facilities in Beneden-Leeuwen. This new cold store near the port of Rotterdam will be operational by mid-2022. This new facility complies with the highest LEED/BREEAM status and will make use of solar energy.
“H&S Coldstores is another fantastic example of our continued investment in the Netherlands,” said Peters of Lineage. “In particular, their differentiated juice-blending services greatly complement our existing capabilities via our recent acquisition of Kloosterboer, and will further diversify our business offering across the cold chain.”
Finally, Lineage also announced today the acquisition of the Dutch facilities of Frigocare Rotterdam BV, a company specialized in handling imports of frozen fish mainly from the North Atlantic and Asia to the Port of Rotterdam. The facility is located near an existing Lineage facility in the same harbour and will add 15,000 pallet positions in its 20,000 square metre warehouses to Lineage’s operations in Rotterdam.
Financial terms of the transactions were not disclosed.
About Lineage Logistics
Lineage Logistics is one of the leading temperature-controlled industrial REIT and logistics solutions providers worldwide. It has a global network of over 400 strategically located facilities totaling over 2 billion cubic feet of capacity which spans 19 countries across North America, Europe and Asia-Pacific. Lineage’s industry-leading expertise in end-to-end logistical solutions, its unrivaled real estate network, and development and deployment of innovative technology help increase distribution efficiency, advance sustainability, minimize supply chain waste, and most importantly, as a Visionary Partner of Feeding America, help feed the world. In recognition of the company’s leading innovations and sustainability initiatives, Lineage was listed as No. 17 in the 2021 CNBC Disruptor 50 list, the No 1. Data Science company, and 23rd overall, on Fast Company’s 2019 list of The World’s Most Innovative Companies, in addition to being included on Fortune’s Change The World list in 2020. (www.lineagelogistics.com)
About Van Tuyl Logistics
Van Tuyl Logistics is a Dutch cold chain logistics company, active in The Netherlands since its inception in 1983. The company specialises in refrigerated and frozen transport of fresh produce and other foodstuffs. Aside from its transport activities, Van Tuyl Logistics also provides storage solutions via their cold storage facility, located in Gameren, The Netherlands.
About H&S Group
H&S Group is Europe’s largest intermodal Liquid Food operator. The company is headquartered in Barneveld, The Netherlands and provides end-to-end supply chain services. H&S Group also offers a pan-European network of more than 250 privately owned and subcontracted vehicles, and more than 1,500 tank units for the liquid foodstuff industry. H&S Coldstores owns three facilities in Tiel, Beneden-Leeuwen and Elst, where it provides the following services: transport, warehousing, customs, production, processing, laboratory testing, and packaging solutions.
About Frigocare Rotterdam
Frigocare Rotterdam BV is a cold store company specialised in food logistics, specifically handling frozen fish from the North Atlantic and Asia to the port of Rotterdam, The Netherlands. The company provides the following services aside from storage: container reception, border inspection, sorting, palletizing, (re)packing and (un)loading of various delicate cargo, mostly seafood, under EU-license.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220110006028/en/
Contact information
Lineage Logistics
Magnus Franklin
+32471620575
magnus.franklin@teneo.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA ™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 14:00:00 EEST | Press release
Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the durable benefit that vimseltinib can offer patients.” Summary of Data and Findings from the 2-year results of the MOTION Phase
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 17:09:00 EEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 17:00:00 EEST | Press release
Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the study increased considerably to 76.2% (95% CI: 63.8, 86.0) by blinded independent review committee (BICR) per RECIST v1.1, from 54% at Week 25. The study also showed continued clinically meaningful improvements in key secondary endpoints related to patient outcomes such as pain and function. The safety profile was consistent with previously reported data. The results are being presented today in the Sarcoma mini-oral session at the European Society for Medical
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 16:04:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B cell-mediated diseases. Pove is the only BAFF+APRIL inhibitor in pivotal trials for multiple kidney diseases. Next Steps for Pove Development In IgAN Following the announcement that the Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) to pove for the treatment of IgAN, FDA recently granted a rolling review of the Biologics License Application (BLA) for pove for this indication. Vertex expects to submit the first module to FDA for potential accelerated approval before t
Qualcomm Announces Quarterly Cash Dividend17.10.2025 16:00:00 EEST | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom